Articles tagged "Graft survival"

2020 American Transplant Congress
Donor and Recipient Sex Affect Transplant Outcomes in an Age-Specific Fashion
R. Maenosono¹, Y. Nian¹, J. Iske¹, Y. Liu¹, H. Azuma², E. Milford³, S. G. Tullius¹
¹Division of Transplant Surgery, Brigham and Women's Hospital, Boston, MA, ²Urology, Osaka Medical College, Osaka, Japan, ³Renal Division, Brigham and Women's Hospital, Boston, MA
*Purpose: Donor and recipient sex impact transplant outcomes. The biology of sex-specific alloimmune responses has not been studied in detail.*Methods: Using clinical data from more…
2020 American Transplant Congress
Steroid Dependence at 1 Yr in Kidney Transplant Recipients Initiated on Early Steroid Withdrawal Protocol: Associated Risk Factors and Prognosis
M. Yaqub, D. Mishler, T. Taber, A. Sharfuddin, W. Goggins, O. Adebiyi
Indiana University, Indianapolis, IN
*Purpose: Early steroid withdrawal (ESW) has become a stable immunosuppression regimen in the USA with a third of patients now discharged steroid-free immediately post-transplant. However,…
2020 American Transplant Congress
Bone Marrow Mesenchymal Stem Cells Improve Rat Islet Angiogenesis by Upregulating of ISL1 and VEGF-A
Y. Wang¹, J. Wang², X. Ding²
¹Department of Renal Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China, ²Department of Renal Transplantation, Nephropathy Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
*Purpose: Islet transplantation is an important therapy to cure diabetes, but poor angiogenesis in the early stage of islet transplantation is one of the main…
2020 American Transplant Congress
Atrial Fibrillation Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: More liver transplants (LT) are being performed in patients >65 years (y) - a population with higher rates of cardiovascular (CV) disease. It is…
2020 American Transplant Congress
Liver Transplantation from Donors after Circulatory Death Using “tPA”Protocol: The University of Miami Experience
R. Vianna, A. Farag, G. Selvaggi, A. Tekin, W. De Faria, M. Morsi, R. Miyashiro, T. Beduschi
University of Miami, Miami Transplant Institute, Miami, FL
*Purpose: Expansion of liver transplantation (LT) from donors after circulatory death (DCD) has been increasingly used to overcome the persistent organ shortage and long waiting…
2020 American Transplant Congress
Graft Survival after Liver Transplantation for Patients with Cholangiocarcinoma
I. A. Ziogas, L. A. Hickman, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. A. Rega, I. D. Feurer, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the treatment for unresectable cholangiocarcinoma (CCA), however, post-LT graft survival is not well described.…
2020 American Transplant Congress
Immune Checkpoint PD-L1 Pathway as an Effective Platform for Localized Immunomodulation to Attain Indefinite Allogeneic Islet Graft Survival
L. Batra¹, P. Shrestha¹, H. Zhao¹, K. B. Woodward¹, M. Tan¹, O. G. Nuno¹, A. Togay¹, M. M. Coronel², A. J. Garcia², H. Shirwan¹, E. S. Yolcu¹
¹Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY, ²Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA
*Purpose: Allogenic islet transplantation is an effective therapeutic approach for the treatment of T1D. However, chronic immunosuppression to control rejection is a major limitation. The…
2020 American Transplant Congress
Renoportal Vein Graft for Complete Portal Vein Thrombosis: A Reproducible Technique for a Challenging Problem
P. Mehta, M. Black, H. Fernandez, J. Bayer, A. Gupta, A. Wall, E. Martinez, N. Onaca, R. Ruiz, G. Testa, G. J. Mckenna
Baylor University Medical Center, Dallas, TX
*Purpose: Type-IV Yerdel portal vein thrombosis (PVT) was historically contraindicated in liver transplant due to lack of appropriate portal vein inflow. Renoportal vein graft (RPVG)…
2020 American Transplant Congress
Changes in Gut Microbiota and Acute Rejection after Kidney Transplantation
H. Cho¹, J. Kim², H. Kim², J. Park³, M. Kwak⁴, B. Kim⁴, D. Kim², J. Lee⁵, B. Kim⁶, H. Lee²
¹Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of, ²Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴ChunLab Inc. Seoul National University, Seoul, Korea, Republic of, ⁵Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Korea, Republic of
*Purpose: Kidney transplantation (KT) is the best treatment for end-stage renal disease. Although rejection is a normal immune response of the body to a foreign…
2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
V. R. Peddi¹, B. Marder², L. Gaite³, J. Oberholzer⁴, R. Goldberg⁵, T. Pearson⁶, H. Yang⁷, L. Allamassey⁸, S. Gao⁸, M. Polinsky⁸, R. N. Formica⁹
¹California Pacific Medical Center, San Francisco, CA, ²Colorado Kidney Care, Denver, CO, ³Hospital Marqués de Valdecilla, Cantabria, Spain, ⁴UVA Health, Charlottesville, VA, ⁵Saint Barnabas Medical Center, Livingston, NJ, ⁶Emory University School of Medicine, Atlanta, GA, ⁷UPMC Pinnacle, Harrisburg, PA, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Yale University School of Medicine, New Haven, CT
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…